Obinutuzumab Biosimilar - Research Grade

Product Specifications

Background

Obinutuzumab biosimilar is a humanized anti-CD20 monoclonal antibody of the IgG1 subclass. It recognizes a specific epitope of the CD20 molecule found on B cells. The molecular mass of the antibody is approximately 150 kDa. it is produced by mammalian cell (CHO) suspension culture. It was engineered for reduced fucose content as compared to a typical IgG1 produced in CHO cells.

Specifications

Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Obinutuzumab/afutuzumab.

Product Name Alternative

B-lymphocyte surface antigen B1, Bp35, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, MS4A1, afutuzumab

UniProt

P11836

Host

Humanized

Species Reactivity

Human

Target

CD20

Isotype

IgG1

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

1.0 - 5.0 mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE and HPLC

Buffer

ICH3001-100mL ICH3002-100mL ICH3003-100mL

Shipping Conditions

Blue ice

Storage Conditions

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.